Yingli Ma, Ph.D.
Chief Technology Officer
Dr. Ma has more than 15 years of research, technology and drug discovery experience in pharma and biotech settings. Prior to joining Structure, Dr. Ma was site head and General Manager of Amgen Biopharmaceutical R&D (Shanghai), responsible for Amgen’s structural biology and China research platforms, supporting all preclinical drug discovery projects including small molecules and biologics in cardiometabolic, oncology and inflammatory disease areas. Prior to Amgen, she was at GSK (Shanghai), supporting multiple preclinical drug discovery programs across a variety of target classes (kinase, PPI, channel, membrane receptor, nuclear receptor etc.) for target validation, protein characterization and structural biology studies in the fields of neuroscience, regenerative medicine and mitochondrial biology. Dr. Ma obtained a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and a B.S. in Clinical Medicine from China Medical University.